Literature DB >> 34001978

Alternative splicing acts as an independent prognosticator in ovarian carcinoma.

Yan Ouyang1, Kaide Xia1,2, Xue Yang1, Shichao Zhang2, Li Wang3, Shan Ren1, Houming Zhou2, Yi Liu4, Fuzhou Tang5.   

Abstract

Alternative splicing (AS) events associated with oncogenic processes present anomalous perturbations in many cancers, including ovarian carcinoma. There are no reliable features to predict survival outcomes for ovarian cancer patients. In this study, comprehensive profiling of AS events was conducted by integrating AS data and clinical information of ovarian serous cystadenocarcinoma (OV). Survival-related AS events were identified by Univariate Cox regression analysis. Then, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis were used to construct the prognostic signatures within each AS type. Furthermore, we established a splicing-related network to reveal the potential regulatory mechanisms between splicing factors and candidate AS events. A total of 730 AS events were identified as survival-associated splicing events, and the final prognostic signature based on all seven types of AS events could serve as an independent prognostic indicator and had powerful efficiency in distinguishing patient outcomes. In addition, survival-related AS events might be involved in tumor-related pathways including base excision repair and pyrimidine metabolism pathways, and some splicing factors might be correlated with prognosis-related AS events, including SPEN, SF3B5, RNPC3, LUC7L3, SRSF11 and PRPF38B. Our study constructs an independent prognostic signature for predicting ovarian cancer patients' survival outcome and contributes to elucidating the underlying mechanism of AS in tumor development.

Entities:  

Year:  2021        PMID: 34001978     DOI: 10.1038/s41598-021-89778-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  24 in total

1.  Alternative expression analysis by RNA sequencing.

Authors:  Malachi Griffith; Obi L Griffith; Jill Mwenifumbo; Rodrigo Goya; A Sorana Morrissy; Ryan D Morin; Richard Corbett; Michelle J Tang; Ying-Chen Hou; Trevor J Pugh; Gordon Robertson; Suganthi Chittaranjan; Adrian Ally; Jennifer K Asano; Susanna Y Chan; Haiyan I Li; Helen McDonald; Kevin Teague; Yongjun Zhao; Thomas Zeng; Allen Delaney; Martin Hirst; Gregg B Morin; Steven J M Jones; Isabella T Tai; Marco A Marra
Journal:  Nat Methods       Date:  2010-09-12       Impact factor: 28.547

2.  The emerging role of splicing factors in cancer.

Authors:  Ana Rita Grosso; Sandra Martins; Maria Carmo-Fonseca
Journal:  EMBO Rep       Date:  2008-10-10       Impact factor: 8.807

3.  MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.

Authors:  Cheryl M Koh; Marco Bezzi; Diana H P Low; Wei Xia Ang; Shun Xie Teo; Florence P H Gay; Muthafar Al-Haddawi; Soo Yong Tan; Motomi Osato; Arianna Sabò; Bruno Amati; Keng Boon Wee; Ernesto Guccione
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

4.  A global survey of alternative splicing in allopolyploid cotton: landscape, complexity and regulation.

Authors:  Maojun Wang; Pengcheng Wang; Fan Liang; Zhengxiu Ye; Jianying Li; Chao Shen; Liuling Pei; Feng Wang; Jiang Hu; Lili Tu; Keith Lindsey; Daohua He; Xianlong Zhang
Journal:  New Phytol       Date:  2017-09-11       Impact factor: 10.151

Review 5.  Expansion of the eukaryotic proteome by alternative splicing.

Authors:  Timothy W Nilsen; Brenton R Graveley
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

6.  Prognostic alternative mRNA splicing signature in non-small cell lung cancer.

Authors:  Yuan Li; Nan Sun; Zhiliang Lu; Shouguo Sun; Jianbing Huang; Zhaoli Chen; Jie He
Journal:  Cancer Lett       Date:  2017-02-20       Impact factor: 8.679

7.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Authors:  Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.

Authors:  Junyong Zhu; Zuhua Chen; Lei Yong
Journal:  Gynecol Oncol       Date:  2017-11-27       Impact factor: 5.482

9.  Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.

Authors:  Emilio Bria; Francesca Di Modugno; Isabella Sperduti; Pierluigi Iapicca; Paolo Visca; Gabriele Alessandrini; Barbara Antoniani; Sara Pilotto; Vienna Ludovini; Jacopo Vannucci; Guido Bellezza; Angelo Sidoni; Giampaolo Tortora; Derek C Radisky; Lucio Crinò; Francesco Cognetti; Francesco Facciolo; Marcella Mottolese; Michele Milella; Paola Nisticò
Journal:  Oncotarget       Date:  2014-11-30

10.  Vex-seq: high-throughput identification of the impact of genetic variation on pre-mRNA splicing efficiency.

Authors:  Scott I Adamson; Lijun Zhan; Brenton R Graveley
Journal:  Genome Biol       Date:  2018-06-01       Impact factor: 13.583

View more
  3 in total

1.  Temporal Modulation of Differential Alternative Splicing in HaCaT Human Keratinocyte Cell Line Chronically Exposed to Arsenic for up to 28 Wk.

Authors:  Ana P Ferragut Cardoso; Mayukh Banerjee; Laila Al-Eryani; Mohammed Sayed; Daniel W Wilkey; Michael L Merchant; Juw W Park; J Christopher States
Journal:  Environ Health Perspect       Date:  2022-01-24       Impact factor: 9.031

2.  Screening and Identification of Survival-Associated Splicing Factors in Lung Squamous Cell Carcinoma.

Authors:  Min Chen; Rui Zhu; Fangzhou Zhang; Liucun Zhu
Journal:  Front Genet       Date:  2022-01-20       Impact factor: 4.599

3.  Comprehensive characterization of 11 prognostic alternative splicing events in ovarian cancer interacted with the immune microenvironment.

Authors:  Congbo Yue; Tianyi Zhao; Shoucai Zhang; Yingjie Liu; Guixi Zheng; Yi Zhang
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.